ClinicalTrials.gg

Program

dazucorilant

Also written as “Dazucorilant”, “Dazucorilant 300 mg” and “Dazucorilant 150 mg”.

Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Corcept Therapeutics.

Furthest: phase 2, since Jun 2, 20226 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Corcept Therapeutics61 open or runningphase 2since Jun 2, 2022Jan 29, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2020First study: phase 1 study in Healthy AdultsFirst studyNCT04249323 · 110 enrolled · United Kingdom
  2. Jul 27, 20212 phase 1 studiesNCT04990310, NCT04994743
  3. Jun 2, 2022Phase 2 study in Amyotrophic Lateral SclerosisNCT05407324 · 279 enrolled · United States, Belgium, Canada and more
  4. Jul 3, 2024Phase 1 study in Healthy AdultsNCT06495944 · 21 enrolled · United States
  5. Apr 8, 2025Phase 1 study in Hepatic ImpairmentNCT06928779 · 19 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06928779Hepatic Impairment · United States1CompletedDec 9, 202419
NCT06495944Healthy Adults · United States1CompletedAug 2, 202421
NCT05407324Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more2Active, not recruitingOct 2026279
NCT04994743Healthy Adults · Netherlands1CompletedSep 30, 202116
NCT04990310Healthy · United Kingdom1CompletedSep 20, 20216
NCT04249323Healthy Adults · United Kingdom1CompletedOct 15, 2020110

How it is read

Names in the registry

  • “Dazucorilant”, 3 entries
  • “Dazucorilant 300 mg”, 1 entry
  • “Dazucorilant 150 mg”, 1 entry
  • “CORT113176 Lipid Capsule Formulation”, 1 entry
  • “[14C]-CORT113176”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
dazucorilant (Corcept Therapeutics): development program | ClinicalTrials.gg